Q3 2023 Results - Reimagining Medicine

Company overview Innovation: Pipeline overview Cardiovascular Financial review Conclusions Financial performance Immunology ianalumab - BAFF-R inhibitor Indication NCT05349214 NEPTUNUS-2 (CVAY736A2302) Sjögren's syndrome Phase Phase 3 Patients 489 Primary Outcome Change from baseline in EULAR Sjögren Syndrome Disease Activity Index (ESSDAI) score at Week 48 as compared to placebo Measures Arms Intervention Target Patients Arm 1: Experimental - ianalumab exposure level 1 Arm 2: Experimental - ianalumab exposure level 2 Arm 3: Placebo comparator Patients with active Sjogren's syndrome Readout Milestone(s) Primary 2026 Publication TBD 56 Investor Relations | Q3 2023 Results Appendix Innovation: Clinical trials Neuroscience Oncology ianalumab - BAFF-R inhibitor NCT05350072 NEPTUNUS-1 (CVAY736A2301) Sjögren's syndrome Indication Phase Phase 3 Patients 268 References Abbreviations Other Primary Outcome Measures Arms Change from baseline in EULAR Sjögren Syndrome Disease Activity Index (ESSDAI) score at Week 48 as compared to placebo Arm 1: Experimental - ianalumab Intervention Arm 2: Placebo comparator Target Patients Patients with active Sjogren's syndrome Readout Milestone(s) Primary 2026 Publication TBD NOVARTIS | Reimagining Medicine

View entire presentation